In the present study, factors related to the recurrence of breast ductal carcinoma in situ (DCIS) in Korean patients were identified, and the prognostic factors for each age group were explored. Methods: The subjects were 226 patients who were diagnosed with DCIS by histopathologic examination, and the effect of representative prognostic factors that are known already, including estrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2) status, Ki-67 levels, and adjuvant therapy on the recurrence of DCIS was analyzed by using the Cox proportional hazard model. Results: Among the 226 subjects, 11 patients underwent the recurrence of breast cancer. The average follow-up period was 52.7 ±23.5 months. The average age of the subjects was 50.6±9.3 years. Among the DCIS patients, the recurrence of breast cancer was significantly higher in the ER negative patients and those who have a Ki-67 level over 20%. However, the PR and HER2 status did not significantly affect breast cancer recurrence. The result also showed that only ER negative was a significant factor before the age of 50 years and that only the Ki-67 level over 20% was a significant factor to the patients 50 years of age or older. Conclusion: DCIS patients should be appropriately treated and managed depending on their age and clinicopathological factors to prevent the recurrence of DCIS.
91.3% in 2008~) Breast cancer is the second most common cancer next to thyroid cancer in Korean women [1,2].The incidence of breast cancer varies according to age. As of 2014, median age at diagnosis was in the 50s but peak incidence was in the 40s (40s > 50s > 60s > 30s > 70s) [3].In Korea, the incidence of breast cancer among premenopausal and younger patients ( < 40 years old) is twice that in Western countries. Furthermore, survival rates of young breast cancer patients are low and recurrences rate are high, and thus it is important the clinical features and prognostic factors of breast cancer in young patients be identified, and that appropriate treatment policies be developed to treat women in their 20s and 30s, which experience rapid physiological changes due to pregnancy, childbirth, and breastfeeding [4].This study was undertaken to assess the clinical characteristics of breast cancer patients aged < 35 years old and to compare these with those of patients ≥ 35 years. METHODSNine hundred and sixty-nine patients that underwent surgery due to invasive ductal carcinoma in the Gil Medical Center from Janu-Purpose: In Korea, the incidence of breast cancer peaks in the fifth decade, which is younger than that observed in the Western world. We conducted this study to compare the clinical characteristics and prognostic factors of breast cancer in women <35 and ≥35 years old. Methods: The medical records of 969 patients treated for breast cancer at the Gil Medical Center from 2008 through 2012 were reviewed. Tumor characteristics, surgical methods, and adjuvant therapies were compared in two groups. Results: Number of childbirths, family history, the proportion of postmenopausal women were lower among those aged <35 years. However, tumor size, number of metastatic lymph nodes, and surgical procedures were similar in two groups. The rate of triple negative status in younger patients was higher than in older patients. Adjuvant chemotherapy was effective in patients positive for hormone receptors and no lymph nodal invasion, and it was effective in patients negative for hormone receptors and lymph nodal invasion in patients aged >35 years old. Postoperative radiotherapy was statistically effective in patients aged <35 and ≥35 years old that underwent breast-conserving surgery. Pregnancy were significantly associated with survival in younger patients. While lymph node stage, presence of progesterone receptor, and triple negative status were significantly associated with survival on older patients. Conclusion: The prognostic factors of breast cancer in patients younger than 35 years old were pregnancy. Triple negative status rate was higher in younger patients than in older patients. Adjuvant therapy had similar effects in patients aged <35 or ≥35 years old.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.